OncoMatch/Clinical Trials/NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Is NCT05908409 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies IDP-121 for multiple myeloma (mm).
Treatment: IDP-121 — The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: concomitant anti-tumor therapy
Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1.
Cannot have received: allogeneic transplantation
Exception: allowed if >3 months prior and no active GVHD with immunosuppressive treatment
Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
Lab requirements
Blood counts
Hemoglobin >8.0 g/dl (no transfusion support within 7 days); Platelets >75 x10^9/L (no transfusion support within 7 days; ≥50 x10^9/L if bone marrow infiltration); ANC >0.75 x10^9/L (no G-CSF support within 7 days)
Kidney function
Creatinine clearance >30 mL/min (Cockcroft-Gault)
Liver function
AST <2.5 x ULN (or <5 x ULN with liver metastases); ALT <2.5 x ULN (or <5 x ULN with liver metastases); total bilirubin <2 x ULN
Cardiac function
Left ventricular ejection fraction >50% or above institutional LLN by echocardiogram
Adequate hematological or biochemical parameters as specified below... Left ventricular ejection fraction >50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05908409 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior concomitant anti-tumor therapy, allogeneic transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify